Compare CRBP & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRBP | VWAV |
|---|---|---|
| Founded | 2009 | 2024 |
| Country | United States | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 148.1M |
| IPO Year | 2014 | N/A |
| Metric | CRBP | VWAV |
|---|---|---|
| Price | $10.10 | $5.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $45.60 | N/A |
| AVG Volume (30 Days) | 201.7K | ★ 392.1K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $4.64 | $2.06 |
| 52 Week High | $20.56 | $15.80 |
| Indicator | CRBP | VWAV |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 40.03 |
| Support Level | $9.86 | N/A |
| Resistance Level | $11.64 | $8.41 |
| Average True Range (ATR) | 0.69 | 0.85 |
| MACD | 0.09 | -0.09 |
| Stochastic Oscillator | 83.54 | 30.35 |
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.